A Canada-specific verification guide built around Health Canada’s peptide warning, the Drug Product Database, and provincial pharmacy licensing.
Health Canada warned in April 2026 that unauthorized injectable peptide drugs sold online can cause serious harm and said products labelled for research use should not be used as drugs.
Use this checklist to verify the local product, seller, and supply records before comparing price or availability.
Authorized drugs sold in Canada carry an eight-digit Drug Identification Number that can be checked in Health Canada’s database.
Use the pharmacy regulatory authority for the province or territory where the business is established, including for online sellers.
Do not treat a ‘research use only’ label, imported parcel, or wellness claim as a prescription or authorization pathway.
Each answer is tied to the local records below so you can see what is confirmed, what remains unknown, and where to recheck it. Open the primary sources ↓
No blanket answer is supportable. Authorized drugs sold in Canada carry an eight-digit Drug Identification Number that can be checked in Health Canada’s database. In Canada, begin with Drug Product Database from Health Canada; the product, seller, and supply route still need to resolve to the same current record.
No. Peptide Local withholds a commercial table for Canada until seller category, local delivery, regulatory or research status, exact price, and observation date are all sourced. This page is a verification route, not a shopping recommendation.
For Canada, start with Drug Product Database from Health Canada, then open Choosing a safe online pharmacy from Health Canada. The records answer separate questions, so confirm each current entry instead of treating one match as proof of the seller, product, and route together.
Resolve the identity first, then use this country’s official product and seller records. A matching name never transfers approval, trial evidence, or seller authority.
KPV is tracked as an unapproved tripeptide identity with preclinical and laboratory evidence. FDA states that neither KPV free base nor KPV acetate is a component of an FDA-approved drug and that it found no published study in which a KPV drug product was administered to humans. A seller listing, formulation, or research label cannot establish clinical benefit, safety, local authorization, or lawful supply.
Primary identity sourceFDA briefing document for KPV-related bulk drug substancesU.S. Food and Drug Administration ↗BPC-157 is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Health Canada names TB-500 among injectable peptide drugs often sold illegally and also records seized products labelled as TB-500 or thymosin beta-4. Those records concern unauthorized products and do not authenticate a different listing, seller, presentation, import route, or supply claim.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Health Canada names GHK-Cu among injectable peptide drugs often sold illegally and records GHK-Cu among unauthorized injectable products seized in Canada. Those records do not authenticate a different listing, seller, presentation, import route, or supply claim.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Semax is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Health Canada names melanotan I and II among injectable peptide drugs often sold illegally and records Melanotan-2 among unauthorized products seized in Canada. Those records do not authenticate a different listing, seller, presentation, import route, or supply claim.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Health Canada names MOTS-c among examples of unauthorized injectable peptide drugs identified or seized in Canada. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Health Canada records a seller-labelled 10 mg tesamorelin product among unauthorized health products seized from a Canadian business. That record does not establish the status or identity of every tesamorelin listing, and it does not transfer the US EGRIFTA WR approval to a research vial.
Primary identity sourceCheck the FDA Purple Book product recordU.S. Food and Drug Administration ↗Health Canada records a seller-labelled 5 mg AOD-9604 product among unauthorized injectable peptide products seized from a Canadian business. That finding does not authenticate or determine the status of a different listing, seller, presentation, or supply route.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Health Canada names ipamorelin among examples of unauthorized injectable peptide drugs identified or seized in Canada. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Selank is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Health Canada records PT-141 among unauthorized injectable peptide products seized in Calgary. That record does not authenticate every same-name listing and does not transfer the identity or approval of the US VYLEESI prescription product to a research vial.
Primary identity sourceRead the current DailyMed drug labelNational Library of Medicine, DailyMed ↗Health Canada names CJC-1295 among examples of unauthorized injectable peptide drugs identified or seized in Canada. The Canadian records do not resolve a seller's DAC versus no-DAC format. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Health Canada names CJC-1295 among examples of unauthorized injectable peptide drugs identified or seized in Canada. The Canadian records do not resolve a seller's DAC versus no-DAC format. The record does not authenticate a different listing, seller, presentation, import route, or supply claim.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗Retatrutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceTRIUMPH-1 Phase 3 study - NCT05929066ClinicalTrials.gov ↗Mazdutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceGLORY-1 Phase 3 study - NCT05607680ClinicalTrials.gov ↗Ecnoglutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSLIMMER Phase 3 study - NCT05813795ClinicalTrials.gov ↗Enicepatide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceCT388-103 Phase 2 study - NCT06525935ClinicalTrials.gov ↗Eloralintide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceEloralintide Phase 2 study - NCT06230523ClinicalTrials.gov ↗Cagrilintide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗Petrelintide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceZUPREME-1 Phase 2 study - NCT06662539ClinicalTrials.gov ↗CagriSema is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceREDEFINE 1 Phase 3 study - NCT05567796ClinicalTrials.gov ↗MariTide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourcePhase 2 dose-ranging study - NCT05669599ClinicalTrials.gov ↗Survodutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceSYNCHRONIZE-1 Phase 3 study - NCT06066515ClinicalTrials.gov ↗VK2735 is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceVENTURE injectable Phase 2 study - NCT06068946ClinicalTrials.gov ↗Pemvidutide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceIMPACT Phase 2b MASH study - NCT05989711ClinicalTrials.gov ↗Amycretin / Zenagamtide is an investigational clinical program. No seller listing in Canada can inherit the sponsor’s clinical identity, trial evidence, or regulatory status. Check any exact product and supplier claim in the destination records below.
Primary identity sourceAMAZE 7 zenagamtide versus semaglutide Phase 3 study - NCT07668414ClinicalTrials.gov ↗Tirzepatide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.
Primary identity sourceCurrent ZEPBOUND prescribing informationNational Library of Medicine, DailyMed ↗Orforglipron / Foundayo begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.
Primary identity sourceCurrent FOUNDAYO prescribing informationNational Library of Medicine, DailyMed ↗Health Canada authorized its first generic semaglutide injection referencing Ozempic in April 2026 and its first generic weight-management semaglutide referencing Wegovy in June 2026. Those decisions belong to exact products and indications. The authorization holder, presentation, current market status, prescription route, pharmacy record, and seller still need to match the current Canadian records linked on this page.
Primary identity sourceCurrent WEGOVY prescribing informationNational Library of Medicine, DailyMed ↗DSIP / Emideltide is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗IGF-1 LR3 is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem substance recordNational Library of Medicine, PubChem ↗Kisspeptin-10 / KP-10 is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Melanotan I is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the current SCENESSE labelNational Library of Medicine, DailyMed ↗NAD+ is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the PubChem compound recordNational Library of Medicine, PubChem ↗Sermorelin is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA orphan-drug recordU.S. Food and Drug Administration ↗Thymosin Alpha-1 is tracked as a US research-market identity, not as an authorization or local supply finding for Canada. Match the exact category, legal seller identity, and claimed route against the official records on this page.
Primary identity sourceRead the FDA sourceU.S. Food and Drug Administration ↗EGRIFTA WR begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.
Primary identity sourceCurrent EGRIFTA WR prescribing informationNational Library of Medicine, DailyMed ↗Liraglutide begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.
Primary identity sourceCurrent SAXENDA prescribing informationNational Library of Medicine, DailyMed ↗SCENESSE begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.
Primary identity sourceCurrent SCENESSE prescribing informationNational Library of Medicine, DailyMed ↗VYLEESI begins here with a US FDA medicine identity. That does not prove the same product, presentation, approval, prescription status, or current availability in Canada. Verify the exact local records below.
Primary identity sourceCurrent VYLEESI prescribing informationNational Library of Medicine, DailyMed ↗Peptide Local will not manufacture a ranking from thin data. A local table appears only after seller category, authorization or research status, delivery market, price, and source date can all be stated clearly.
Official sources are linked directly. Open them to confirm the current record; this page is a guide, not a substitute for the regulator.